Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315941 | 1.00 | MAPK1 (0.41) | MAPK1MEN1KMT2APOLBGAA | |
| SCHEMBL1164960 | 1.00 | MAPK1 (0.41) | MAPK1MEN1KMT2APOLBGAA | |
| SCHEMBL17101416 | 0.91 | MAPK1 (0.54) | MAPK1MEN1KMT2APOLBGAA | |
| SCHEMBL935034 | 0.86 | MEN1 (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL1573560 | 0.80 | MAPK1 (0.33) | MAPK1MEN1KMT2A | |
| SCHEMBL30359026 | 0.80 | MAPK1 (0.33) | MAPK1MEN1KMT2A | |
| SCHEMBL25244282 | 0.80 | MAPK1 (0.33) | MAPK1MEN1KMT2A | |
| SCHEMBL17101422 | 0.79 | MAPK1 (0.40) | MAPK1MEN1KMT2A | |
| SCHEMBL12357441 | 0.79 | MAPK1 (0.45) | MAPK1MEN1KMT2A | |
| SCHEMBL17101420 | 0.79 | MAPK1 (0.40) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892800-A1 | 3- (1,2,3,4-TETRAHYDROISOQUINOLINE-2-YL)METHYL]-8-AZABICYCLO 3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SYNTHELABO (FR) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038998-A1 | 3-[(1,2,3,4-TETRAHYDROISOQUINOLINE-2-YL)METHYL]-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SYNTHELABO (FR) | 1997-10-23 | — | — | WO | claimed |
| US-11981686-B2 | Urea compound having substituent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-14 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3915558-A1 | SUBSTITUENT-INCLUDING UREA COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003084954-A1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-6531484-B2 | Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS | MERCK & CO., INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-26 | — | — | US | disclosed |
| EP-1242421-A1 | 4-[ARYL(8-AZABICYCLO[3.2.1] OCTAN-3-YL)] AMINOBENZOIC ACID DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046191-A1 | 4-[ARYL(8-AZABICYCLO[3.2.1]OCTAN-3-YL)]AMINOBENZOIC ACID DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0892800-A1 | 3- (1,2,3,4-TETRAHYDROISOQUINOLINE-2-YL)METHYL]-8-AZABICYCLO 3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SYNTHELABO (FR) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038998-A1 | 3-[(1,2,3,4-TETRAHYDROISOQUINOLINE-2-YL)METHYL]-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SYNTHELABO (FR) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981686-B2 | Urea compound having substituent | SIRT6, SIRT1, SIRT2 | MAPK1 373/4885MEN1 1143/4885KMT2A 289/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | MAPK1 2377/4885MEN1 627/4885KMT2A 2042/4885 |
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | MAPK1 902/4885MEN1 4803/4885KMT2A 4691/4885 |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | MAPK1 373/4885MEN1 1143/4885KMT2A 289/4885 |
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM4, CHRM2 | MAPK1 2093/4885MEN1 695/4885KMT2A 2013/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MAPK1 1782/4885MEN1 3572/4885KMT2A 2317/4885 |
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CCL5 | MAPK1 762/4885MEN1 4563/4885KMT2A 4134/4885 |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | MAPK1 3855/4885MEN1 3922/4885KMT2A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.